UBS Group
ACRS icon

UBS Group’s Aclaris Therapeutics ACRS Stock Holding History

UBS Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,400
Closed -$148K – 9460
2021
Q2 		$148K Hold
8,400
– – ﹤0.01% 5578
2021
Q1 		$212K Buy
+8,400
New +$164K ﹤0.01% 5441
2019
Q3 		– Sell
-103,000
Closed -$226K – 7947
2019
Q2 		$226K Buy
+103,000
New +$561K ﹤0.01% 4847

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

UBS Group's ACRS Position: Q2 2026 in Review

UBS Group increased its Aclaris Therapeutics (ACRS) stake by 24% in Q2 2026, buying an estimated $224K and bringing the position to 257,001 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #5459.

UBS Group first reported a position in ACRS in Q4 2015 and has held it in 43 quarters since. The position peaked at $9.73M in Q4 2018. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • UBS Group held 257,001 shares of Aclaris Therapeutics worth $1.36M as of Q2 2026.
  • UBS Group bought 50,187 Aclaris Therapeutics shares in Q2 2026, an estimated $224K.
  • Aclaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5459 holding.
  • UBS Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • UBS Group's Aclaris Therapeutics position peaked at $9.73M in Q4 2018.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.